NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Cetuximab for the treatment of advanced non-small cell lung cancer

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:						
Provi	Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:						
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:	
1.	Afiya Trust	NICE secretariat		Included	As per the inclusion criteria this organisation has been added to the matrix	
2.	Black Health Agency	NICE secretariat		Included	As per the inclusion criteria this organisation has been added to the matrix	

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of cetuximab for the treatment of advanced non-small cell lung cancer

British Ethnic Health Awareness Foundation (BEHAF)	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
British Geriatrics Society	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
CANCERactive	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Chinese National Healthy Living Centre	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Confederation of Indian Organisations	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Equalities National Council	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of cetuximab for the treatment of advanced non-small cell lung cancer

Helen Rollason Heal Cancer Charity	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Hospira	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Maggie's Centres	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Muslim Council of Great Britain	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Muslim Health Network	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
National Association of Primary Care	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of cetuximab for the treatment of advanced non-small cell lung cancer

National Cancer Research Network	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
National Institute for Health Research	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
NHS Alliance	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Policy Research Institute on Ageing and Ethnicity	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix
Research Institute for the Care of Older People	NICE secretariat	Included	As per the inclusion criteria this organisation has been added to the matrix

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of cetuximab for the treatment of advanced non-small cell lung cancer

,	South Asian Health Foundation	NICE secretariat	Included	As per the inclusion criteria this
				organisation has been added to the
				matrix

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of cetuximab for the treatment of advanced non-small cell lung cancer